Business
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announced the online publication of the first-in-human Phase I trial (NCT05790694/CTR20221961) of HBM9378 (also known as SKB378 or WIN378), led by Dr. Min Xu, Physician in Respiratory Medicine at Chengdu Fifth People's Hospital, in the peer-reviewed journal Drug Design, Development and Therapy.
About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
[{"type":"text","content":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announced the online publication of the first-in-human Phase I trial (NCT05790694/CTR20221961) of HBM9378 (also known as SKB378 or WIN378), led by Dr. Min Xu, Physician in Respiratory Medicine at Chengdu Fifth People's Hospital, in the peer-reviewed journal Drug Design, Development and Therapy. The favorable safety profile and extended half-life observed in this study support further exploration of HBM9378's effects in patients with severe immunological disorders.","length":786,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Harbour BioMed)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Harbour BioMed)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":159,"url":"https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QfTD0HAZLEeUnnuJyHFWgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MA--/https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a","width":400,"height":159}},"href":"https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"HBM9378 is a novel, half-life extended fully human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP) jointly developed by Harbour BioMed and Kelun-Biotech. In the randomized, double-blind, placebo-controlled, single-ascending-dose (SAD) study, 50 healthy adult subjects were enrolled to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378. The dose-escalation study enrolled ten healthy subjects per cohort (20 mg, 60 mg, 200 mg, 600 mg, and 900 mg), with eight receiving HBM9378 and two receiving the placebo at each dose level.","length":583,"tagName":"p"},{"type":"text","content":"Data showed that the incidence of treatment-emergent adverse events (TEAEs) was comparable between the HBM9378 dose groups and the placebo group, with no trend for increasing safety risks with dose escalation. The median time to maximum concentration...
More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H